Monogram Technologies Inc. SEC 10-Q Report

Monogram Technologies Inc., a company specializing in advanced robotic systems for orthopedic surgeries, has released its Form 10-Q report for the second quarter of 2025. The report provides a comprehensive overview of the company's financial performance and key business developments during this period.

Financial Highlights

Product Revenue: $0 million. The company did not have any product sales during the three and six months ended June 30, 2025, and 2024.

Gross Profit: $0 million. No gross profit was recorded as there were no product sales.

Loss from Operations: $(3.1) million for the three months ended June 30, 2025, a decrease from $(3.6) million in the same period in 2024, primarily due to reduced operating expenses.

Net Loss: $(5.4) million for the three months ended June 30, 2025, an increase from $(3.5) million in the same period in 2024, driven by a $2.5 million increase in the expense accrual related to terminating the Mt. Sinai License Agreement.

Net Loss Per Share: $(0.16) for the three months ended June 30, 2025, compared to $(0.11) in the same period in 2024, reflecting the increased net loss.

Business Highlights

New Product Launches: Monogram Technologies Inc. announced that the FDA granted 510(k) clearance for its Monogram mBôs™ TKA System on March 17, 2025. This clearance allows the company to market the device, marking a significant milestone in its product development.

Pending Merger: The company entered into a Merger Agreement with Zimmer Biomet Holdings, Inc. on July 11, 2025. This merger will result in Monogram becoming a wholly-owned subsidiary of Zimmer Biomet, subject to certain conditions.

Regulatory Update: The company received regulatory approval from India’s Central Drugs Standard Control Organization to conduct a 102-patient clinical investigation of its Monogram TKA System, in collaboration with Shalby Limited.

Geographical Performance: The company is focusing on initial placements of its FDA-cleared mBôs™ TKA System with key surgeon KOLs in strategic geographies to establish clinical experience and demonstrate the system’s advantages.

Future Outlook: Monogram plans to integrate recent upgrades to its cutting system and other enhancements into the cleared mBôs™ TKA System, aiming for strategic market adoption and positioning for new opportunities.

Macroeconomic and Geopolitical Environment: The company is monitoring potential impacts from new tariffs and geopolitical tensions, which could affect future operations, including costs for components and materials.

Operational Strategy: Monogram is committed to a disciplined, long-term commercialization strategy, focusing on strategic market adoption and leveraging its FDA-cleared robotic system to de-risk its platform and validate its technology.

SEC Filing: Monogram Technologies Inc. [ MGRM ] - 10-Q - Aug. 15, 2025